+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics

  • ID: 5025060
  • Report
  • March 2020
  • Region: Global
  • 357 Pages
  • Roots Analysis
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • 2-BBB
  • BBB Therapeutics
  • DelMar Pharmaceuticals
  • Johnson & Johnson
  • NeuroTransit
  • Sandoz
  • MORE

Overview

According to a study conducted by the World Health Organization (WHO), diseases that affect the central nervous system (CNS), such as Alzheimer’s disease, brain cancer, multiple sclerosis. Parkinson’s disease and stroke, are characterized by a significant unmet need for effective treatment options. In 2019, it was reported that nearly 1.5 billion people suffer from some form of disorder affecting the CNS across the globe. In fact, the incidence of CNS disorders is anticipated to increase by 12% by 2030. In 2019, nearly 5.8 million Americans were reported to have been diagnosed with Alzheimer’s disease. Similarly, Parkinson’s disease was estimated to affect nearly one million people in America, with approximately 60,000 new patients being diagnosed every year. Further, experts believe that there is a critical relationship between recent pandemic of novel Coronavirus (COVID-19) and the cardiovascular and cerebrovascular systems. People suffering from certain CNS complications are at a relatively higher risk of COVID-19 infection due to a compromised immune system.

It is estimated that CNS disorders are responsible for a healthcare burden of nearly USD 2 trillion, in the US and Europe. Developing viable therapies against the aforementioned clinical conditions is largely complicated due to the elusive blood-brain barrier (BBB), a selectively permeable structure, which is very effective in preventing the entry of foreign substances, including drugs, into the brain. It has been reported that over 1,000 currently available / under development drugs targeting CNS disorders do not have the potential to target specific brain receptors responsible for the disease progression due to the hindrance by the BBB. Considering the serious physical, cognitive and psychosocial consequences that such indications have on patients, coupled to the alarming increase in their global prevalence, there is an urgent need for novel and effective treatment options that can cross the BBB.

Over time, extensive R&D efforts have resulted in the development of a number of versatile BBB penetration technologies. These technologies have been designed either to externally alter the permeability of the BBB or augment the BBB penetrating capabilities of compatible pharmacological interventions. As a result, presently, there is a lot of enthusiasm within the medical science community related to these technologies. The growing interest in this field is also evident in the fact that over 1,200 modern scientific articles have been published (as observed on NCBI’s PubMed portal) over the last three years alone. However, it is worth mentioning that there are currently no approved BBB penetrating drugs available in the market. Currently, this niche market is driven by technology licensing activity, with drug developers collaborating with platform providers to grow their respective therapeutic pipelines. In fact, over the last 4-5 years, there has been a marked rise in the number of new entrants in this field. We anticipate this upcoming market to witness substantial growth in the coming years.

Scope of the Report

The ‘Blood-Brain Barrier (BBB) Market, 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics (2nd Edition) (based on Receptor Mediated Transcytosis, Trojan Horse, and Nanoparticle based Approaches)’ report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of BBB penetration technologies and affiliated drugs, over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.

In addition to other elements, the study includes:

  • An overview of the overall landscape of BBB penetration technologies, featuring an in-depth analysis of the technologies based on a number of parameters, such as status of development (developed and under development), affiliated approach, type of compatible pharmacological molecule(s) crossing the BBB (small molecule and biologic), target receptor(s), target disease indication(s), patent availability, and licensing activity. In addition, it presents a detailed assessment of BBB technology developers and analyses based on parameters, such as year of establishment, company size, and location of headquarters.
  • A detailed assessment of the current market landscape of BBB penetrant drugs (based on the abovementioned technologies), providing information on drug developer(s) (such as year of establishment, company size, and location of headquarters), phase of development (clinical, preclinical, and discovery stage), type of molecule (small molecule and biologic), affiliated BBB penetration technology, route of administration (oral, intravenous, transmucosal and others), target disease indication(s), key therapeutic area(s), and information on special drug designation (if any).
  • Identification of contemporary market trends, depicted using three schematic representations, which include [A] a tree map representation of the various industry players involved in the development of BBB penetrant drugs, distributed on the basis of the target disease indication(s) of pipeline candidates and size of the companies (small, mid-sized and large companies), [B] a bubble analysis comparing the leading players engaged in the development of BBB penetrant drugs, on the basis of parameters such as pipeline strength (based on the number of drug candidates developed by a particular company, across different phases of development), number of target disease indication(s) and the size of the developer company, and [C] an informative heptagon representation, highlighting the distribution of BBB penetrant drugs across popular target disease indication(s) (based on the number of drug candidates across each target disease indication).
  • An insightful competitiveness analysis of BBB penetration technologies, taking into consideration the supplier power (based on company size and years of experience in this field) and key technology specific information, such as type of compatible pharmacological molecule(s) crossing the BBB, availability of patent protection, number of deals signed for a particular technology (2014-2020 (till March)), and popularity of the technology (in terms of the number of drugs developed using the technology).
  • Elaborate profiles of prominent technology developers that are engaged in the development of at least four drugs (which are presently in both preclinical and clinical stages of development), featuring a brief overview of the company, its financial information (if available), BBB penetration technology overview, BBB penetrant product portfolio and an informed future outlook.
  • An analysis of the partnerships that have been established in the domain, in the period between 2014 and 2020 (till March), covering product licensing agreements, technology licensing agreements, acquisitions and mergers, product development and commercialization agreements, research and development agreements, manufacturing agreements, service agreements and other agreements.
  • An elaborate discussion on the deal structures of various types of technology licensing agreements inked in this domain, including details of the rights associated with product ownership, associated royalties and upfront payments, and other contractual terms/conditions involved as a part of the agreement between various industry stakeholders.
  • An analysis of the investments made in the domain, in the period between 2014 and 2020 (till March), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are engaged in this field.
  • An in-depth analysis of the various patents that have been filed/granted related to BBB penetration technologies, till November 2019, taking into consideration various parameters, such as patent type, application year, issuing authority/patent offices involved, CPC symbols, emerging focus areas, type of organization and leading industry / academic players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.
  • An insightful chessboard analysis highlighting the most preferred/popular drug development strategies/paths adopted by majority of the drug developers (with clinical candidates) in order to progress their lead drug candidates.
  • An assessment of the most commonly targeted disorders affecting the CNS (shortlisted on the basis of number of BBB penetrant drugs in development), along with [A] an insightful 3D bubble chart highlighting the market potential of these disorders, based on the number of already approved drugs, number of pipeline drugs and the target patient population, and [B] an elaborate discussion on key epidemiological facts about specific diseases, causes, symptoms, details of BBB penetrant drugs that are being developed against them, currently available treatment options and details of already marketed drugs for each indication.
  • A list of 240+ drug developers targeting Alzheimer’s disease and Parkinson’s disease that are likely to partner with BBB penetration technology providers, and have been shortlisted on the basis of parameters, such as developer strength (based on company size and years of experience in this field), company’s pipeline strength and maturity (based on the number of drugs and affiliated stage of development), indication overlap, molecule type overlap, route of administration, mechanism of action, and the availability of in-house delivery technology.
  • A case study highlighting the working principle of the most common approaches that are being employed for the development of BBB penetration technologies, such as receptor mediated transcytosis (RMT) (including bispecific antibodies and molecular trojan horse mediated delivery either by direct coupling or using nanocarriers), increasing permeability to the BBB, passive diffusion approach, and other novel approaches (including cell-penetrating peptides, macrocycles, and organ-on-a-chip technology).
  • An informative analysis of contemporary Google Trends in the time period between 2015 and 2019 (till December) and insights generated from recent news articles related to the BBB, indicating the increasing popularity of this domain.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for BBB penetration technologies and affiliated therapeutics, over the next decade. Based on likely licensing deal structures and agreements that are expected to be inked in the foreseen future, we have provided an informed estimate of the evolution of the market for the period 2020-2030. In addition, we have provided information on (potential) sales-based revenues generated by BBB penetrant drugs that are currently in late stages of development for the treatment of different CNS disorders, based on parameters, such as target consumer segments, likely adoption rates, expected pricing and associated risk-adjustment sales opportunity. The report also features the likely distribution of the current and forecasted opportunity across [A] type of molecule (small molecules and biologics), [B] target disease indications (brain metastases in breast cancer, glioblastoma multiforme, Hurlers syndrome, and Hunter syndrome), [C] key contributing technologies, [D] leading drug developers, and [E] key geographical regions (North America, Europe, Asia-Pacific and rest of the world). In order to account for the uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were also influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Ram Bhatt (Chief Executive Officer, Chairman and Founder, Innovative California Biosciences International (ICBI))
  • Frank S Walsh (Chief Executive Officer and Founder, Ossianix)
  • Pieter Gaillard (Chief Executive Officer and Co-Founder, 2-BBB)
  • Mathias Schmidt (Chief Executive Officer, ArmaGen)
  • Rob Hutchison (Chief Executive Officer and Chairman, biOasis Technologies)
  • Mark L Peterson (Chief Operating Officer, Cyclenium Pharma)
  • Xavier Rivero (Chief Operating Officer, Sagetis Biotech)
  • Carole Desseaux (Head of Clinical Affairs, CarThera)
  • Jamal Temsamani (Head of Drug Development, Vect-Horus)
  • Kevin Kit Parker (Professor, Wyss Institute, Harvard University)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading developers of BBB penetrating drugs and technologies?
  • What are the key BBB penetrating technologies (available / under development) for delivery of CNS drugs?
  • What are the key challenges faced by stakeholders engaged in this domain?
  • Which partnership models are commonly adopted by stakeholders in this industry?
  • Who are the most likely partners for BBB penetrating technology providers?
  • What different strategies are used by BBB drug developers?
  • What is the trend of capital investments in BBB related R&D?
  • How is the current and future market opportunity likely to be distributed across key market segments?
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 2-BBB
  • BBB Therapeutics
  • DelMar Pharmaceuticals
  • Johnson & Johnson
  • NeuroTransit
  • Sandoz
  • MORE

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Structure of the Human Brain
3.3. Global Burden on Neurological Disorders and Impact of Coronavirus Disease (COVID-19)
3.4. Strategies for Drug Delivery to the Central Nervous System (CNS)
3.4.1. Invasive Techniques
3.4.1.1. Systemic Administration of Therapeutics
3.4.1.2. Direct Administration of Therapeutics
3.4.1.3. Intracerebral Devices and Implants
3.4.2. Non-Invasive Techniques / Approaches
3.4.2.1. Liposomes
3.4.2.2. Exosomes
3.4.2.3. Prodrugs
3.4.2.4. Nanoparticles and Microspheres
3.4.2.5. Novel Formulations and Conjugates
3.4.3. Chemical Delivery Systems
3.5. Blood-Brain Barrier (BBB)
3.5.1. Key Historical Milestones
3.5.2. Structure and Key Components
3.5.3. Key Functions
3.6. Strategies for Drug Delivery across the BBB
3.6.1. Increasing Permeability by Temporary Disruption of the BBB
3.6.2. Pharmacological Strategies to Facilitate Transport Across the BBB
3.7. Challenges Associated with BBB Penetration and CNS Drug Delivery
3.8. Prevalent Trends Related to Non-Invasive BBB Penetration Technologies
3.8.1. Emerging Focus Areas
3.8.2. Key Historical Trends
3.8.3. Geographical Activity
3.9. Concluding Remarks

4. MARKET LANDSCAPE: NON-INVASIVE BBB PENETRATION
4.1. Chapter Overview
4.2. Non-Invasive BBB Penetration Technologies: Overall Market Landscape
4.2.1. Analysis by Status of Development
4.2.2. Analysis by Underlying Principle
4.2.3. Analysis by Compatible Pharmacological Molecule(s)
4.2.4. Analysis by Target Receptor(s)
4.2.5. Analysis by Target Disease Indication(s)
4.2.6. Analysis by Patent Availability
4.2.7. Analysis by Licensing Activity
4.3. Non-Invasive BBB Penetration Technology Providers: Overall Market Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters

5. MARKET LANDSCAPE: BBB PENETRATING DRUGS
5.1. Chapter Overview
5.2. BBB Penetrating Drugs: Development Pipeline
5.2.1. Analysis by Phase of Development
5.2.2. Analysis by Type of Molecule
5.2.3. Analysis by Affiliated BBB Penetration Technology
5.2.4. Analysis by Route of Administration
5.2.5. Analysis by Target Disease Indication(s)
5.2.6. Analysis by Therapeutic Area(s)
5.3. BBB Penetrating Drugs: Additional Information
5.4. BBB Penetrating Drug Developers: Overall Market Landscape
5.4.1. Analysis by Year of Establishment
5.4.2. Analysis by Company Size
5.4.3. Analysis by Location of Headquarters
5.4.4. Leading Drug Developers: Analysis by Number of Drugs
5.4.5. Leading Drug Developers: 4D Bubble Analysis based on Pipeline Strength, Target Disease Indication and Company Size
5.4.6. Heptagon Representation: Analysis by Phase of Development and Key Disease Indications
5.4.7. Tree Map Representation: Analysis by Key Disease Indications and Size of the Company

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Leading Players based in North America
6.2.1. Angiochem
6.2.1.1. Company Overview
6.2.1.2. Technology Overview
6.2.1.3. Product Portfolio
6.2.1.4. Recent Developments and Future Outlook
6.2.2. ArmaGen
6.2.2.1. Company Overview
6.2.2.2. Technology Overview
6.2.2.3. Product Portfolio
6.2.2.4. Recent Developments and Future Outlook
6.2.3. Denali Therapeutics
6.2.3.1. Company Overview
6.2.3.2. Technology Overview
6.2.3.3. Product Portfolio
6.2.3.4. Recent Developments and Future Outlook
6.2.4. ICB International
6.2.4.1. Company Overview
6.2.4.2. Technology Overview
6.5.4.3. Product Portfolio
6.2.4.4. Recent Developments and Future Outlook
6.2.5. Lauren Sciences
6.2.5.1. Company Overview
6.2.5.2. Technology Overview
6.2.5.3. Product Portfolio
6.2.5.4. Recent Developments and Future Outlook
6.3. Leading Players based in Europe
6.3.1. BioArctic
6.3.1.1. Company Overview
6.3.1.2. Technology Overview
6.3.1.3. Product Portfolio
6.3.1.4. Recent Developments and Future Outlook
6.3.2. Cyclenium Pharma
6.3.2.1. Company Overview
6.3.2.2. Technology Overview
6.3.2.3. Product Portfolio
6.3.2.4. Recent Developments and Future Outlook
6.3.3. Iproteos
6.3.3.1. Company Overview
6.3.3.2. Technology Overview
6.3.3.3. Product Portfolio
6.3.3.4. Recent Developments and Future Outlook
6.3.4. Medesis Pharma
6.3.4.1. Company Overview
6.3.4.2. Technology Overview
6.3.4.3. Product Portfolio
6.3.4.4. Recent Developments and Future Outlook
6.3.5. Ossianix
6.3.5.1. Company Overview
6.3.5.2. Technology Overview
6.3.5.3. Product Portfolio
6.3.5.4. Recent Developments and Future Outlook
6.3.6. Vect-Horus
6.3.6.1. Company Overview
6.3.6.2. Technology Overview
6.3.6.3. Product Portfolio
6.3.6.4. Recent Developments and Future Outlook
6.4. Leading Players based in Asia-Pacific
6.4.1. JCR Pharmaceuticals
6.4.1.1. Company Overview
6.4.1.2. Technology Overview
6.4.1.3. Product Portfolio
6.4.1.4. Recent Developments and Future Outlook

7. TECHNOLOGY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Methodology and Key Parameters
7.3. BBB Penetration Technologies: Platform Competitiveness Analysis

8. NON-INVASIVE BBB PENETRATION TECHNOLOGIES: POPULAR APPROACHES
8.1. Chapter overview
8.2. Receptor Mediated Transcytosis (RMT)
8.2.1. Type of Target Receptors
8.2.1.1. Diphtheria Toxin Receptor
8.2.1.2. Insulin Receptor and Insulin-like Growth Factor Receptor
8.2.1.3. Low Density Lipoprotein Receptor-Related Proteins (LRP-1 and LRP-2)
8.2.1.4. Transferrin Receptor
8.2.2. Types of RMT Approaches
8.2.2.1. Bispecific Antibody-based Approach
8.2.2.2. Molecular Trojan Horse-based Approach
8.2.2.2.1. Important Considerations for Designing Molecular Trojan Horses
8.2.2.2.2. Considerations for Designing a Trojan Horse Liposome (THL)
8.2.2.2.3. Popular Conjugation Strategies
8.2.2.2.3.1. Direct Coupling Approach
8.2.2.2.3.2. Nanoparticles-based Approach
8.3. Increasing the Permeability of the BBB
8.3.1. Use of Ultrasound Waves
8.3.2. Use of High-Frequency Electric Field
8.4. Passive Diffusion
8.5. Novel Approaches
8.5.1. Cell Penetrating Peptides
8.5.2. Macrocycles
8.5.3. Organ-on-a-Chip Technology

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Non-Invasive BBB Technologies and Drugs: List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Analysis by Focus Area
9.3.6. Analysis by Type of Molecule
9.3.7. Analysis by Target Disease Indication
9.3.8. Most Active Players: Analysis by Number of Partnerships
9.3.9. Most Popular Technologies: Analysis by Number of Partnerships
9.3.10. Regional Analysis
9.3.11. Intercontinental and Intracontinental Agreements

10. ANALYSIS OF RECENT LICENSING AGREEMENTS
10.1. Chapter Overview
10.2. Licensing Agreements: Definition and Importance in Pharmaceutical Industry
10.3. Types of Licensing Agreements
10.3.1. Out-Licensing Agreements
10.3.2. In-Licensing Agreements
10.4. Components of Licensing Agreements
10.5. Recent Examples of BBB-Related Technology Licensing Agreements
10.5.1. Analysis by Year of Agreement
10.5.2. Analysis by Type of Licensing Agreement
10.5.3. Analysis by Type of Owner
10.5.4. Most Active Players: Analysis by Number of Licensing Agreements
10.5.5. Most Popular Technologies: Analysis by Number of Licensing Agreements
10.5.6. Regional Analysis
10.5.7. Intercontinental and Intracontinental Licensing Agreements
10.6. Case-in-Point: Technology Licensing Timeline
10.6.1. Sumitomo Dainippon Pharma and JCR Pharmaceuticals
10.6.2. Denali Therapeutics and Sanofi
10.6.3. biOasis Technologies and Prothena
10.6.4. Vect-Horus and Janssen Pharmaceuticals
10.7. Concluding Remarks

11. FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding
11.3. Non-Invasive BBB Penetration Technologies and Drugs: List of Funding and Investments
11.3.1. Analysis by Number of Instances
11.3.2. Analysis by Amount Invested
11.3.3. Analysis by Type of Funding
11.3.4. Analysis by Type of Company
11.3.5. Analysis by Purpose of Funding
11.3.6. Analysis by Type of Molecule
11.3.7. Analysis by Target Disease Indication
11.3.8. Analysis by Geography
11.3.9. Most Active Players: Analysis by Number of Funding Instances
11.3.10. Most Popular Technologies: Analysis by Number of Funding Instances
11.3.11. Most Active Investors: Analysis by Number of Funding Instances
11.4. Concluding Remarks

12. PATENT ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Non-Invasive BBB Penetration Technologies: Patent Analysis
12.3.1. Analysis by Application Year
12.3.1.1. Analysis by Filed Patent Applications
12.3.1.2. Analysis by Granted Patent Applications
12.3.2. Analysis by Issuing Authority / Patent Offices Involved
12.3.3. Analysis by CPC Symbols
12.3.4. Emerging Focus Areas
12.3.5. Analysis by Type of Organization
12.3.6. Leading Assignees: Analysis by Number of Patents
12.4. Non-Invasive BBB Technologies: Patent Valuation Analysis

13. DRUG DEVELOPMENT STRATEGY ANALYSIS
13.1. Chapter Overview
13.2 Scope and Methodology
13.3. Strategies Adopted by Late-Stage Drug Candidates
13.3.1. Drug A
13.3.2. Drug B
13.3.3. Drug C
13.3.4. Drug D
13.4. Concluding Remarks

14. MARKET POTENTIAL OF KEY NEUROLOGICAL DISORDERS
14.1. Chapter Overview
14.2. Market Potential of Key Neurological Disorders: 3D Bubble Chart Analysis
14.3. Key Neurological Disorders: Detailed Information
14.3.1. Alzheimer’s Disease
14.3.1.1. Disease Description
14.3.1.2. Epidemiology
14.3.1.3. Symptoms
14.3.1.4. Current Treatment Options
14.3.1.5. BBB Penetrating Drugs for Alzheimer’s Disease
14.3.1.6. Roots Analysis Perspective
14.3.2. Brain Cancer
14.3.2.1. Disease Description
14.3.2.2. Epidemiology
14.3.2.3. Symptoms
14.3.2.4. Current Treatment Options
14.3.2.4.1. Surgery
14.3.2.4.2. Radiation Therapy
14.3.2.4.3. Systemic Therapy
14.3.2.5. BBB Penetrating Drugs for Brain Cancer
14.3.2.6. Roots Analysis Perspective
14.3.3. Multiple Sclerosis
14.3.3.1. Disease Description
14.3.3.2. Epidemiology
14.3.3.3. Symptoms
14.3.3.4. Current Treatment Options
14.3.3.4.1. Treatment for Attacks
14.3.3.4.2. Treatments to Modify Progression
14.3.3.4.3. Interferons
14.3.3.5. BBB Penetrating Drugs for Multiple Sclerosis
14.3.3.6. Roots Analysis Perspective
14.3.4. Parkinson’s Disease
14.3.4.1. Disease Description
14.3.4.2. Epidemiology
14.3.4.3. Symptoms
14.3.4.4. Current Treatment Options
14.3.4.4.1. Pharmacological Management of Parkinson’s Disease
14.3.4.4.2. Non-Pharmacological Management of Parkinson’s Disease
14.3.4.4.3. Management of Parkinson’s Disease using Dietary Supplements
14.3.4.5. BBB Penetrating Drugs for Parkinson’s Disease
14.3.4.6. Roots Analysis Perspective

15. LIKELY PARTNER ANALYSIS
15.1. Chapter Overview
15.2. Scope and Methodology
15.3. Potential Strategic Partners for Drug Development
15.3.1. Opportunities in North America
15.3.1.1. Most Likely Partners
15.3.1.2. Likely Partners
15.3.1.3. Less Likely Partners
15.3.2. Opportunities in Europe
15.3.2.1. Most Likely Partners
15.3.2.2. Likely Partners
15.3.2.3. Less Likely Partners
15.3.3. Opportunities in Asia-Pacific and Rest of the World
15.3.3.1. Most Likely Partners
15.3.3.2. Likely Partners
15.3.3.3. Less Likely Partners

16. MARKET FORECAST
16.1. Chapter Overview
16.2. Forecast Methodology and Key Assumptions
16.3. Overall BBB Penetration Technologies Market, 2020-2030
16.3.1. BBB Penetration Technologies Market: Contribution from Upfront Payments, 2020-2030
16.3.2. BBB Penetration Technologies Contribution from Milestone Payments, 2020-2030
16.4. Overall BBB Penetrating Drugs Market, 2020-2030
16.4.1. BBB Penetrating Drugs Market: Distribution by Type of Molecule
16.4.1.1. BBB Penetrating Drugs Market for Small Molecules, 2020-2030
16.4.1.2. BBB Penetrating Drugs Market for Biologics, 2020-2030
16.4.2. BBB Penetrating Drugs Market: Distribution by Target Disease Indication
16.4.2.1. BBB Penetrating Drugs Market for Brain Metastases in Breast Cancer, 2020-2030
16.4.2.2. BBB Penetrating Drugs Market for Glioblastoma Multiforme, 2020-2030
16.4.2.3. BBB Penetrating Drugs Market for Hunter Syndrome, 2020-2030
16.4.2.4. BBB Penetrating Drugs Market for Hurler Syndrome, 2020-2030
16.4.3. BBB Penetrating Drugs Market: Distribution by Key Geographical Regions
16.4.3.1. BBB Penetrating Drugs Market in North America, 2020-2030
16.4.3.2. BBB Penetrating Drugs Market in Europe, 2020-2030
16.4.3.3. BBB Penetrating Drugs Market in Asia-Pacific and Rest of the World, 2020-2030
16.4.4. BBB Penetrating Drugs Market: Distribution by Leading Technology Platforms
16.4.5. BBB Penetrating Drugs Market: Distribution by Leading Drug Developers
16.5.6. Drug-wise Sales Forecast
16.5.6.1. 2B3-101 / 2X-111 (2X Oncology)
16.5.6.1.1. Sales Forecast (USD Million)
16.5.6.1.2. Risk-Adjusted Market Opportunity (USD Million)
16.5.6.1.3. Net Present Value (USD Million)
16.5.6.1.4. Value Creation Analysis
16.5.6.2. AGT-181 (ArmaGen)
16.5.6.2.1. Sales Forecast (USD Million)
16.5.6.2.2. Risk-Adjusted Market Opportunity (USD Million)
16.5.6.2.3. Net Present Value (USD Million)
16.5.6.2.4. Value Creation Analysis
16.5.6.3. AGT-182 (ArmaGen)
16.5.6.3.1. Sales Forecast (USD Million)
16.5.6.3.2. Risk-Adjusted Market Opportunity (USD Million)
16.5.6.3.3. Net Present Value (USD Million)
16.5.6.3.4. Value Creation Analysis
16.5.6.4. ANG1005 (Angiochem)
16.5.6.4.1. Sales Forecast (USD Million)
16.5.6.4.2. Risk-Adjusted Market Opportunity (USD Million)
16.5.6.4.3. Net Present Value (USD Million)
16.5.6.4.4. Value Creation Analysis
16.5.6.5. JR-141 (JCR Pharmaceuticals)
16.5.6.5.1. Sales Forecast (USD Million)
16.5.6.5.2. Risk-Adjusted Market Opportunity (USD Million)
16.5.6.5.3. Net Present Value (USD Million)
16.5.6.5.4. Value Creation Analysis

17. CONCLUSION
17.1. Chapter Overview
17.2. Key Takeaways

18. EXECUTIVE INSIGHTS
18.1. Chapter Overview
18.2. Innovative California Biosciences International (ICBI)
18.2.1. Company Snapshot
18.2.2. Interview Transcript: Ram Bhatt, Chief Executive Officer, Chairman and Founder
18.3. Ossianix
18.3.1. Company Snapshot
18.3.2. Interview Transcript: Frank S Walsh, Chief Executive Officer and Founder
18.4. 2-BBB
18.4.1. Company Snapshot
18.4.2. Interview Transcript: Pieter Gaillard, Chief Executive Officer and Co-Founder
18.5. ArmaGen
18.5.1. Company Snapshot
18.5.2. Interview Transcript: Mathias Schmidt, Chief Executive Officer
18.6. biOasis Technologies
18.6.1. Company Snapshot
18.6.2. Interview Transcript: Rob Hutchison, Chief Executive Officer
18.7. Cyclenium Pharma
18.7.1. Company Snapshot
18.7.2. Interview Transcript: Mark L Peterson, Chief Operating Officer
18.8. Sagetis Biotech
18.8.1. Company Snapshot
18.8.2. Interview Transcript: Xavier Rivero, Chief Operating Officer
18.9. CarThera
18.9.1. Company Snapshot
18.9.2. Interview Transcript: Carole Desseaux, Head of Clinical Affairs
18.10. Vect-Horus
18.10.1. Company Snapshot
18.10.2. Interview Transcript: Jamal Temsamani, Head of Drug Development
18.11. Wyss Institute, Harvard University
18.11.1. Organization Snapshot
18.11.2. Interview Transcript: Kevin Kit Parker, Professor

19. APPENDIX I: TABULATED DATA

List Of Figures
Figure 3.1 Structure of the Human Brain
Figure 3.2 Common Neurological Disorders
Figure 3.3 Important Statistics Related to Neurological Disorders
Figure 3.4 Strategies for Drug Delivery to the Central Nervous System (CNS)
Figure 3.5 Key Historical Milestones in BBB Research
Figure 3.6 Pathway Associated with the BBB
Figure 3.7 Transport Systems Associated with the BBB
Figure 3.8 Google Trends Analysis: Emerging Focus Areas
Figure 3.9 Google Trends Analysis: Historical Timeline
Figure 3.10 Google Trends Analysis: Geographical Activity
Figure 4.1 Non-Invasive BBB Penetration Technologies: Distribution by Status of Development
Figure 4.2 Non-Invasive BBB Penetration Technologies: Distribution by Underlying Principle
Figure 4.3 Non-Invasive BBB Penetration Technologies: Distribution by Compatible Pharmacological Molecule(s)
Figure 4.4 Non-Invasive BBB Penetration Technologies: Distribution by Target Receptor(s)
Figure 4.5 Non-Invasive BBB Penetration Technologies: Distribution by Target Disease Indication(s)
Figure 4.6 Non-Invasive BBB Penetration Technologies: Distribution by Patent Availability
Figure 4.7 Non-Invasive BBB Penetration Technologies: Distribution by Licensing Activity
Figure 4.8 Non-Invasive BBB Technology Providers: Distribution by Year of Establishment
Figure 4.9 Non-Invasive BBB Technology Providers: Distribution by Company Size
Figure 4.10 Non-Invasive BBB Technology Providers: Distribution by Location of Headquarters
Figure 5.1 BBB Penetrating Drugs: Distribution by Phase of Development
Figure 5.2 BBB Penetrating Drugs: Distribution by Type of Molecule
Figure 5.3 BBB Penetrating Drugs: Distribution by Affiliated BBB Penetration Technology
Figure 5.4 BBB Penetrating Drugs: Distribution by Route of Administration
Figure 5.5 BBB Penetrating Drugs: Distribution by Target Disease Indication(s)
Figure 5.6 BBB Penetrating Drugs: Distribution by Therapeutic Area(s)
Figure 5.7 BBB Penetrating Drug Developers: Distribution by Year of Establishment
Figure 5.8 BBB Penetrating Drug Developers: Distribution by Company Size
Figure 5.9 BBB Penetrating Drug Developers: Distribution by Location of Headquarters
Figure 5.10 Leading Drug Developers: Distribution by Number of Drugs
Figure 5.11 Leading Drug Developers: 4D Bubble Analysis based on Pipeline Strength, Target Disease Indication and Company Size
Figure 5.12 Heptagon Representation: Distribution by Phase of Development and Key Disease Indications
Figure 5.13 Tree Map Representation: Distribution by Key Disease Indications and Size of the Company
Figure 7.1 BBB Penetration Technologies: Platform Competitiveness Analysis
Figure 8.1 Receptor Mediated Transcytosis (RMT): Key Functions
Figure 8.2 RMT: Working Mechanism
Figure 8.3 Molecular Trojan Horse-based Approach: Working Mechanism
Figure 9.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2014-Q1 2020
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Year-Wise Trend by Type of Partnership
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.5 Partnerships and Collaborations: Year-Wise Trend by Type of Partner
Figure 9.6 Partnerships and Collaborations: Distribution by Type of Partner and Partnership Model
Figure 9.7 Partnerships and Collaborations: Distribution by Focus Area
Figure 9.8 Partnerships and Collaborations: Distribution by Type of Molecule
Figure 9.9 Partnerships and Collaborations: Year-Wise Trend by Type of Molecule
Figure 9.10 Partnerships and Collaborations: Distribution by Target Disease Indication
Figure 9.11 Partnerships and Collaborations: Year-Wise Trend by Target Disease Indication
Figure 9.12 Partnerships and Collaborations: Distribution by Target Disease Indication and Partnership Model
Figure 9.13 Most Active Players: Distribution by Number of Partnerships
Figure 9.14 Most Popular Technologies: Distribution by Number of Partnerships
Figure 9.15 Partnerships and Collaborations: Regional Distribution
Figure 9.16 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 10.1 Key Risks and Benefits Associated with a Licensee
Figure 10.2 Key Risks and Benefits Associated with a Licensor
Figure 10.3 Licensing Agreements: Distribution of Financial Components
Figure 10.4 BBB-Related Technology Licensing Agreements: Cumulative Year-Wise Trend, Pre-2014-Q1 2020
Figure 10.5 BBB-Related Technology Licensing Agreements: Distribution by Type of Licensing Agreement
Figure 10.6 BBB-Related Technology Licensing Agreements: Distribution by Type of Owner
Figure 10.7 Most Active Players: Distribution by Number of Licensing Agreements
Figure 10.8 BBB-Related Technology Licensing Agreements: Regional Analysis
Figure 10.9 BBB-Related Technology Licensing Agreements: Intercontinental and Intracontinental Agreements
Figure 10.10 BBB-Related Technology Licensing Agreements: Technology Providers’ Perspective
Figure 11.1 Funding and Investment Analysis: Distribution of Companies by Year of Establishment and Type of Funding, Pre-2014-Q1 2020
Figure 11.2 Funding and Investment Analysis: Cumulative Number of Instances by Year, Pre-2014-Q1 2020
Figure 11.3 Funding and Investment Analysis: Distribution by Type of Funding and Year of Investment, Pre-2014-Q1 2020
Figure 11.4 Funding and Investment Analysis: Cumulative Amount Invested, Pre-2014-Q1 2020 (USD Million)
Figure 11.5 Funding and Investment Analysis: Year-Wise Distribution by Amount Invested and Type of Funding, Pre-2014-Q1 2020 (USD Million)
Figure 11.6 Funding and Investment Analysis: Distribution of Instances by Type of Funding, Pre-2014-Q1 2020
Figure 11.7 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, Pre-2014-Q1 2020 (USD Million)
Figure 11.8 Funding and Investment Analysis: Summary of Amount Invested, Pre-2014-Q1 2020 (USD Million)
Figure 11.9 Funding and Investment Analysis: Distribution by Total Amount Invested and Type of Company, Pre-2014-Q1 2020 (USD Million)
Figure 11.10 Funding and Investment Analysis: Distribution of the Total Amount Invested by Purpose of Funding, Pre-2014-Q1 2020 (USD Million)
Figure 11.11 Funding and Investment Analysis: Distribution of Instances by Type of Molecule, Pre-2014-Q1 2020
Figure 11.12 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Molecule, Pre-2014-Q1 2020 (USD Million)
Figure 11.13 Funding and Investment Analysis: Distribution by Target Disease Indication
Figure 11.14 Funding and Investment Analysis: Distribution of the Total Amount Invested by Target Disease Indication, Pre-2014-Q1 2020 (USD Million)
Figure 11.15 Funding and Investment Analysis: Distribution by Geography
Figure 11.16 Funding and Investment Analysis: Regional Distribution by Total Amount Invested, Pre-2014-Q1 2020
Figure 11.17 Most Active Players: Distribution by Number of Funding Instances and Amount Raised (USD Million)
Figure 11.18 Most Active Technologies: Distribution by Number of Funding Instances and Amount Raised (USD Million)
Figure 11.19 Most Active Investors: Distribution by Number of Funding Instances
Figure 11.20 Funding and Investment Summary, Pre-2014-Q1 2020 (USD Million)
Figure 12.1 Patent Portfolio: Distribution by Type of Patent
Figure 12.2 Patent Portfolio: Cumulative Distribution by Application Year, 2011-2019
Figure 12.3 Patent Portfolio: Distribution of Filed Patents by Application Year, 2011-2019
Figure 12.4 Patent Portfolio: Distribution of Granted Patents by Application Year, 2011-2019
Figure 12.5 Patent Portfolio: Distribution by Issuing Authority / Patent Offices Involved
Figure 12.6 Patent Portfolio: Distribution by CPC Symbols
Figure 12.7 Patent Portfolio: Emerging Focus Areas
Figure 12.8 Patent Portfolio: Cumulative Distribution by Type of Organization
Figure 12.9 Leading Patent Assignees: Distribution by Number of Patents
Figure 12.10 Patent Portfolio: Leading Non-Industry Players in Terms of Number of Patents
Figure 12.11 Patent Portfolio: Distribution by Patent Age (2000-2019)
Figure 12.12 Patent Portfolio: Distribution based on Proprietary Scoring Criteria
Figure 12.13 Patent Portfolio: Valuation Analysis
Figure 13.1 Commercial Development Strategies Adopted for Drug A
Figure 13.2 Commercial Development Strategies Adopted for Drug B
Figure 13.3 Commercial Development Strategies Adopted for Drug C
Figure 13.4 Commercial Development Strategies Adopted for Drug D
Figure 13.5 BBB Penetrating Drug Developers: Popular Development Strategies
Figure 14.1 Market Potential of Key Neurological Disorders: 3D Bubble Analysis based on Number of Approved Drugs, Pipeline Strength and Target Patient Population
Figure 14.2 Normal Brain versus Diseased Brain
Figure 14.3 Alzheimer’s Disease: Phases of Disease Progression
Figure 14.4 Global Dementia-Related Statistics: 2015 and 2030 (Millions)
Figure 14.5 Alzheimer’s Disease: Signs and Symptoms
Figure 14.6 Alzheimer’s Disease: Dietary Supplements
Figure 14.7 Market Potential of Alzheimer’s Disease: 3D Bubble Analysis based on Number of Approved Drugs, Pipeline Strength and Target Patient Population
Figure 14.8 Brain Cancer: Signs and Symptoms
Figure 14.9 Market Potential of Brain Cancer: 3D Bubble Analysis based on Number of Approved Drugs, Pipeline Strength and Target Patient Population
Figure 14.10 Multiple Sclerosis: Signs and Symptoms
Figure 14.11 Market Potential of Multiple Sclerosis: 3D Bubble Analysis based on Number of Approved Drugs, Pipeline Strength and Target Patient Population
Figure 14.12 Parkinson’s Disease: Causal Environmental Factors
Figure 14.13 Parkinson’s Disease: Gender-wise Incidence Rates
Figure 14.14 Parkinson’s Disease: Disease Stages
Figure 14.15 Parkinson’s Disease: Motor Symptoms
Figure 14.16 Parkinson’s Disease: Secondary Symptoms
Figure 14.17 Parkinson’s Disease Management: Non-Pharmacological Treatment Options
Figure 14.18 Parkinson’s Disease Management: Surgical Methods
Figure 14.19 Parkinson’s Disease Management: Dietary Supplements
Figure 14.20 Market Potential of Parkinson’s Disease: 3D Bubble Analysis based on Number of Approved Drugs, Pipeline Strength and Target Patient Population
Figure 16.1 Technology Licensing: Distribution of Financial Components
Figure 16.2 Technology Licensing: Likely Market Evolution
Figure 16.3 BBB Penetration Technologies: Average Volume and Value of Upfront Payments (Units, USD Million)
Figure 16.4 BBB Penetration Technologies: Average Volume and Value of Milestone Payments (Units, USD Million)
Figure 16.5 Overall BBB Penetration Technologies Market, 2020-2030 (USD Million)
Figure 16.6 Overall BBB Penetrating Drugs Market, 2020-2030 (USD Million)
Figure 16.7 BBB Penetrating Drugs Market: Distribution by Type of Molecule, 2020 and 2030
Figure 16.8 BBB Penetrating Drugs Market for Small Molecules, 2020-2030 (USD Million)
Figure 16.9 BBB Penetrating Drugs Market for Biologics, 2020-2030 (USD Million)
Figure 16.10 BBB Penetrating Drugs Market: Distribution by Target Disease Indication, 2020 and 2030
Figure 16.11 BBB Penetrating Drugs Market for Brain Metastases in Breast Cancer, 2020-2030 (USD Million)
Figure 16.12 BBB Penetrating Drugs Market for Glioblastoma Multiforme, 2020-2030 (USD Million)
Figure 16.13 BBB Penetrating Drugs Market for Hunter Syndrome, 2020-2030 (USD Million)
Figure 16.14 BBB Penetrating Drugs Market for Hurler Syndrome, 2020-2030 (USD Million)
Figure 16.15 BBB Penetrating Drugs Market: Distribution by Key Geographical Regions, 2020 and 2030
Figure 16.16 BBB Penetrating Drugs Market in North America, 2020-2030 (USD Million)
Figure 16.17 BBB Penetrating Drugs Market in Europe, 2020-2030 (USD Million)
Figure 16.18 BBB Penetrating Drugs Market in Asia-Pacific and Rest of the World, 2020-2030 (USD Million)
Figure 16.19 BBB Penetrating Drugs Market: Distribution by Leading Technology Platforms, 2020 and 2030
Figure 16.20 BBB Penetrating Drugs Market: Distribution by Leading Drug Developers, 2020 and 2030
Figure 16.21 2B3-101 / 2X-111 (2X Oncology): Sales Forecast, till 2030 (USD Million)
Figure 16.22 2B3-101 / 2X-111 (2X Oncology): Risk-Adjusted Market Opportunity, till 2030 (USD Million)
Figure 16.23 AGT-181 (ArmaGen): Sales Forecast, till 2030 (USD Million)
Figure 16.24 AGT-181 (ArmaGen): Risk-Adjusted Market Opportunity, till 2030 (USD Million)
Figure 16.25 AGT-182 (ArmaGen): Sales Forecast, till 2030 (USD Million)
Figure 16.26 AGT-182 (ArmaGen): Risk-Adjusted Market Opportunity, till 2030 (USD Million)
Figure 16.27 ANG1005 (Angiochem): Sales Forecast, till 2030 (USD Million)
Figure 16.28 ANG1005 (Angiochem): Risk-Adjusted Market Opportunity, till 2030 (USD Million)
Figure 16.29 JR-141 (JCR Pharmaceuticals): Sales Forecast, till 2030 (USD Million)
Figure 16.30 JR-141 (JCR Pharmaceuticals): Risk-Adjusted Market Opportunity, till 2030 (USD Million)

List Of Tables
Table 3.1 Key Components of the Human Brain
Table 3.2 Commercially Available Devices for CNS Drug Delivery
Table 3.3 Key Differences: Non-Invasive and Invasive BBB Technologies
Table 3.4 List of Key Constituents of the BBB
Table 3.5 Key Functions of the BBB
Table 3.6 List of Blood to Brain Transporters
Table 4.1 Non-Invasive BBB Penetration Technologies: List of Technology Platforms
Table 4.2 Non-Invasive BBB Penetration Technologies: List of Technology Providers
Table 5.1 BBB Penetrating Drugs: Development Pipeline
Table 5.2 BBB Penetrating Drugs: Additional Information
Table 5.3 BBB Penetrating Drugs: List of Drug Developers
Table 6.1 Non-Invasive BBB Penetration Technologies and Drugs: List of Companies Profiled
Table 6.2 Angiochem: Company Overview
Table 6.3 Angiochem: Product Portfolio
Table 6.4 Angiochem: Recent Developments and Future Outlook
Table 6.5 ArmaGen: Company Overview
Table 6.6 ArmaGen: Product Portfolio
Table 6.7 ArmaGen: Recent Developments and Future Outlook
Table 6.8 Denali Therapeutics: Company Overview
Table 6.9 Denali Therapeutics: Product Portfolio
Table 6.10 Denali Therapeutics: Recent Developments and Future Outlook
Table 6.11 ICB International: Company Overview
Table 6.12 ICB International: Product Portfolio
Table 6.13 ICB International: Recent Developments and Future Outlook
Table 6.14 Lauren Sciences: Company Overview
Table 6.15 Lauren Sciences: Product Portfolio
Table 6.16 Lauren Sciences: Recent Developments and Future Outlook
Table 6.17 BioArctic: Company Overview
Table 6.18 BioArctic: Product Portfolio
Table 6.19 BioArctic: Recent Developments and Future Outlook
Table 6.20 Cyclenium Pharma: Company Overview
Table 6.21 Cyclenium Pharma: Product Portfolio
Table 6.22 Cyclenium Pharma: Recent Developments and Future Outlook
Table 6.23 Iproteos: Company Overview
Table 6.24 Iproteos: Product Portfolio
Table 6.25 Iproteos: Recent Developments and Future Outlook
Table 6.26 Medesis Pharma: Company Overview
Table 6.27 Medesis Pharma: Product Portfolio
Table 6.28 Medesis Pharma: Recent Developments and Future Outlook
Table 6.29 Ossianix: Company Overview
Table 6.30 Ossianix: Product Portfolio
Table 6.31 Ossianix: Recent Developments and Future Outlook
Table 6.32 Vect-Horus: Company Overview
Table 6.33 Vect-Horus: Product Portfolio
Table 6.34 Vect-Horus: Recent Developments and Future Outlook
Table 6.35 JCR Pharmaceuticals: Company Overview
Table 6.36 JCR Pharmaceuticals: Product Portfolio
Table 6.37 JCR Pharmaceuticals: Recent Developments and Future Outlook
Table 9.1 Non-Invasive BBB Penetration Technologies and Drugs: Partnerships and Collaborations, Information on Partnership Type, Year and Type of Partner, till Q1 2020
Table 9.2 Non-Invasive BBB Penetration Technologies and Drugs: Partnerships and Collaborations, Information on Type of Molecule, Target Indication and Focus Area, till Q1 2020
Table 10.1 List of BBB-Related Technology Licensing Agreements, till Q1 2020
Table 10.2 Licensing Agreement Details: Sumitomo Dainippon Pharma and JCR Pharmaceuticals
Table 10.3 Licensing Agreement Details: Denali Therapeutics and Sanofi
Table 10.4 Licensing Agreement Details: biOasis Technologies and Prothena
Table 10.5 Licensing Agreement Details: Vect-Horus and Janssen Pharmaceuticals
Table 11.1 Non-Invasive BBB Penetration Technologies and Drugs: Funding and Investments, Information on Funding Type, Year, Amount and Investor, till Q1 2020
Table 11.2 Non-Invasive BBB Penetration Technologies and Drugs: Funding and Investments, Information on Type of Molecule, Target Indication and Focus Area, till Q1 2020
Table 12.1 Patent Portfolio: Definitions of CPC Symbols
Table 12.2 Patent Portfolio: Most Popular CPC Symbols
Table 14.1 Alzheimer’s Disease: List of Marketed Drugs
Table 14.2 Alzheimer’s Disease: List of BBB Penetrating Drugs
Table 14.3 Brain Cancer: List of Marketed Drugs
Table 14.4 Brain Cancer: List of BBB Penetrating Drugs
Table 14.5 Multiple Sclerosis: List of Marketed Drugs
Table 14.6 Multiple Sclerosis: List of BBB Penetrating Drugs
Table 14.7 Parkinson’s Disease: List of Marketed Drugs
Table 14.8 Parkinson’s Disease: List of BBB Penetrating Drugs
Table 15.1 Opportunities in North America: Most Likely Partners
Table 15.2 Opportunities in North America: Likely Partners
Table 15.3 Opportunities in North America: Less Likely Partners
Table 15.4 Opportunities in Europe: Most Likely Partners
Table 15.5 Opportunities in Europe: Likely Partners
Table 15.6 Opportunities in Europe: Less Likely Partners
Table 15.7 Opportunities in Asia-Pacific and Rest of the World: Most Likely Partners
Table 15.8 Opportunities in Asia-Pacific and Rest of the World: Likely Partners
Table 15.9 Opportunities in Asia-Pacific and Rest of the World: Less Likely Partners
Table 16.1. Technology Licensing Agreements: Tranches of Milestone Payments
Table 16.2. BBB-Related Technology Licensing Agreements: Average Upfront Payments and Average Milestone Payments, Pre-2014-Q1 2020 (USD Million)
Table 16.3. BBB Penetrating Drugs: Promising Drug Candidates
Table 16.4. BBB Penetrating Drugs Forecast Assumptions: Price Estimations in Key Geographies
Table 16.5. 2B3-101 / 2X-111 (2X Oncology): Net Present Value (USD Million)
Table 16.6. 2B3-101 / 2X-111 (2X Oncology): Value Creation Analysis (USD Million)
Table 16.7. AGT-181 (ArmaGen): Net Present Value (USD Million)
Table 16.8. AGT-181 (ArmaGen): Value Creation Analysis (USD Million)
Table 16.9. AGT-182 (ArmaGen): Net Present Value (USD Million)
Table 16.10. AGT-182 (ArmaGen): Value Creation Analysis (USD Million)
Table 16.11. ANG1005 (Angiochem): Net Present Value (USD Million)
Table 16.12. ANG1005 (Angiochem): Value Creation Analysis (USD Million)
Table 16.13. JR-141 (JCR Pharmaceuticals): Net Present Value (USD Million)
Table 16.14. JR-141 (JCR Pharmaceuticals): Value Creation Analysis (USD Million)
Table 17.1 BBB Penetrating Drugs and Technologies: Key Takeaways of the Report
Table 18.1 ICBI: Company Snapshot
Table 18.2 Ossianix: Company Snapshot
Table 18.3 2-BBB: Company Snapshot
Table 18.4 ArmaGen: Company Snapshot
Table 18.5 biOasis Technologies: Company Snapshot
Table 18.6 Cyclenium Pharma: Company Snapshot
Table 18.7 Sagetis Biotech: Company Snapshot
Table 18.8 CarThera: Company Snapshot
Table 18.9 Vect-Horus: Company Snapshot
Table 18.10 Wyss Institute, Harvard University: Company Snapshot
Table 19.1 Important Statistics Related to Neurological Disorders
Table 19.2 Non-Invasive BBB Penetration Technologies: Distribution by Status of Development
Table 19.3 Non-Invasive BBB Penetration Technologies: Distribution by Underlying Principle
Table 19.4 Non-Invasive BBB Penetration Technologies: Distribution by Compatible Pharmacological Molecule(s)
Table 19.5 Non-Invasive BBB Penetration Technologies: Distribution by Target Receptor(s)
Table 19.6 Non-Invasive BBB Penetration Technologies: Distribution by Target Disease Indication(s)
Table 19.7 Non-Invasive BBB Penetration Technologies: Distribution by Patent Availability
Table 19.8 Non-Invasive BBB Penetration Technologies: Distribution by Licensing Activity
Table 19.9 Non-Invasive BBB Technology Providers: Distribution by Year of Establishment
Table 19.10 Non-Invasive BBB Technology Providers: Distribution by Company Size
Table 19.11 Non-Invasive BBB Technology Providers: Distribution by Location of Headquarters
Table 19.12 BBB Penetrating Drugs: Distribution by Phase of Development
Table 19.13 BBB Penetrating Drugs: Distribution by Type of Molecule
Table 19.14 BBB Penetrating Drugs: Distribution by Affiliated BBB Penetration Technology
Table 19.15 BBB Penetrating Drugs: Distribution by Route of Administration
Table 19.16 BBB Penetrating Drugs: Distribution by Target Disease Indication(s)
Table 19.17 BBB Penetrating Drugs: Distribution by Therapeutic Area(s)
Table 19.18 BBB Penetrating Drug Developers: Distribution by Year of Establishment
Table 19.19 BBB Penetrating Drug Developers: Distribution by Company Size
Table 19.20 BBB Penetrating Drug Developers: Distribution by Location of Headquarters
Table 19.21 Leading Drug Developers: Distribution by Number of Drugs
Table 19.22 Heptagon Representation: Distribution by Phase of Development and Key Disease Indications
Table 19.23 Tree Map Representation: Distribution by Key Disease Indications and Size of the Company
Table 19.24 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre--2014-Q1 2020
Table 19.25 Partnerships and Collaborations: Distribution by Type of Partnership
Table 19.26 Partnerships and Collaborations: Year-Wise Trend by Type of Partnership
Table 19.27 Partnerships and Collaborations: Distribution by Type of Partner
Table 19.28 Partnerships and Collaborations: Year-Wise Trend by Type of Partner
Table 19.29 Partnerships and Collaborations: Distribution by Type of Partner and Partnership Model
Table 19.30 Partnerships and Collaborations: Distribution by Focus Area
Table 19.31 Partnerships and Collaborations: Distribution by Type of Molecule
Table 19.32 Partnerships and Collaborations: Year-Wise Trend by Type of Molecule
Table 19.33 Partnerships and Collaborations: Distribution by Target Disease Indication
Table 19.34 Partnerships and Collaborations: Year-Wise Trend by Target Disease Indication
Table 19.35 Partnerships and Collaborations: Distribution by Target Disease Indication and Partnership Model
Table 19.36 Most Active Players: Distribution by Number of Partnerships
Table 19.37 Most Popular Technologies: Distribution by Number of Partnerships
Table 19.38 Partnerships and Collaborations: Regional Distribution
Table 19.39 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 19.40 BBB-Related Technology Licensing Agreements: Cumulative Year-Wise Trend, Pre-2014-Q1 2020
Table 19.41 BBB-Related Technology Licensing Agreements: Distribution by Type of Licensing Agreement
Table 19.42 BBB-Related Technology Licensing Agreements: Distribution by Type of Owner
Table 19.43 Most Active Players: Distribution by Number of Licensing Agreements
Table 19.44 BBB-Related Technology Licensing Agreements: Regional Analysis
Table 19.45 BBB-Related Technology Licensing Agreements: Intercontinental and Intracontinental Agreements
Table 19.46 Funding and Investment Analysis: Distribution of Companies by Year of Establishment and Type of Funding, Pre-2014-Q1 2020
Table 19.47 Funding and Investment Analysis: Cumulative Number of Instances by Year, Pre-2014-Q1 2020
Table 19.48 Funding and Investment Analysis: Distribution by Type of Funding and Year of Investment, Pre-2014-Q1 2020
Table 19.49 Funding and Investment Analysis: Cumulative Amount Invested, Pre-2014-Q1 2020 (USD Million)
Table 19.50 Funding and Investment Analysis: Year-Wise Distribution by Amount Invested and Type of Funding, Pre-2014-Q1 2020 (USD Million)
Table 19.51 Funding and Investment Analysis: Distribution of Instances by Type of Funding, Pre-2014-Q1 2020
Table 19.52 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, Pre-2014-Q1 2020 (USD Million)
Table 19.53 Funding and Investment Analysis: Distribution by Total Amount Invested and Type of Company, Pre-2014-Q1 2020 (USD Million)
Table 19.54 Funding and Investment Analysis: Distribution of the Total Amount Invested by Purpose of Funding, Pre-2014-Q1 2020 (USD Million)
Table 19.55 Funding and Investment Analysis: Distribution of Instances by Type of Molecule, Pre-2014-Q1 2020
Table 19.56 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Molecule, Pre-2014-Q1 2020 (USD Million)
Table 19.57 Funding and Investment Analysis: Distribution by Target Disease Indication
Table 19.58 Funding and Investment Analysis: Distribution of the Total Amount Invested by Target Disease Indication, Pre-2014-Q1 2020 (USD Million)
Table 19.59 Funding and Investment Analysis: Distribution by Geography
Table 19.60 Funding and Investment Analysis: Regional Distribution by Total Amount Invested, Pre-2014-Q1 2020
Table 19.61 Most Active Players: Distribution by Number of Funding Instances and Amount Raised (USD Million)
Table 19.62 Most Active Technologies: Distribution by Number of Funding Instances and Amount Raised (USD Million)
Table 19.63 Most Active Investors: Distribution by Number of Funding Instances
Table 19.64 Funding and Investment Summary, Pre-2014-Q1 2020 (USD Million)
Table 19.65 Patent Portfolio: Distribution by Type of Patent
Table 19.66 Patent Portfolio: Cumulative Distribution by Application Year, 2011-2019
Table 19.67 Patent Portfolio: Distribution of Filed Patents by Application Year, 2011-2019
Table 19.68 Patent Portfolio: Distribution of Granted Patents by Application Year, 2011-2019
Table 19.69 Patent Portfolio: Distribution by Issuing Authority / Patent Offices Involved
Table 19.70 Patent Portfolio: Distribution by CPC Symbols
Table 19.71 Patent Portfolio: Cumulative Distribution by Type of Organization
Table 19.72 Leading Patent Assignees: Distribution by Number of Patents
Table 19.73 Patent Portfolio: Leading Non-Industry Players in Terms of Number of Patents
Table 19.74 Patent Portfolio: Distribution by Patent Age (2000-2019)
Table 19.75 Patent Portfolio: Valuation Analysis
Table 19.76 Global Dementia-Related Statistics: 2015 and 2030 (Millions)
Table 19.77 BBB Penetration Technologies: Average Volume and Value of Upfront Payments (Units, USD Million)
Table 19.78 BBB Penetration Technologies: Average Volume and Value of Milestone Payments (Units, USD Million)
Table 19.79 Overall BBB Penetration Technologies Market, Conservative, Base and Optimistic Scenario, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.80 Overall BBB Penetrating Drugs Market, Conservative, Base and Optimistic Scenario, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.81 BBB Penetrating Drugs Market: Distribution by Type of Molecule, 2020 and 2030
Table 19.82 BBB Penetrating Drugs Market for Small Molecules, Conservative, Base and Optimistic Scenario, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.83 BBB Penetrating Drugs Market for Biologics, Conservative, Base and Optimistic Scenario, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.84 BBB Penetrating Drugs Market: Distribution by Target Disease Indication, 2020 and 2030
Table 19.85 BBB Penetrating Drugs Market for Brain Metastases in Breast Cancer, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.86 BBB Penetrating Drugs Market for Glioblastoma Multiforme, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.87 BBB Penetrating Drugs Market for Hunter Syndrome, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.88 BBB Penetrating Drugs Market for Hurler Syndrome, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.89 BBB Penetrating Drugs Market: Distribution by Key Geographical Regions, 2020 and 2030
Table 19.90 BBB Penetrating Drugs Market in North America, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.91 BBB Penetrating Drugs Market in Europe, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.92 BBB Penetrating Drugs Market in Asia-Pacific and Rest of the World, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.93 BBB Penetrating Drugs Market: Distribution by Leading Technology Platforms, 2020 and 2030
Table 19.94 BBB Penetrating Drugs Market: Distribution by Leading Drug Developers, 2020 and 2030
Table 19.95 2B3-101 / 2X-111 (2X Oncology): Sales Forecast, till 2030 (USD Million)
Table 19.96 2B3-101 / 2X-111 (2X Oncology): Risk-Adjusted Market Opportunity, till 2030 (USD Million)
Table 19.97 AGT-181 (ArmaGen): Sales Forecast, till 2030 (USD Million)
Table 19.98 AGT-181 (ArmaGen): Risk-Adjusted Market Opportunity, till 2030 (USD Million)
Table 19.99 AGT-182 (ArmaGen): Sales Forecast, till 2030 (USD Million)
Table 19.100 AGT-182 (ArmaGen): Risk-Adjusted Market Opportunity, till 2030 (USD Million)
Table 19.101 ANG1005 (Angiochem): Sales Forecast, till 2030 (USD Million)
Table 19.102 ANG1005 (Angiochem): Risk-Adjusted Market Opportunity, till 2030 (USD Million)
Table 19.103 JR-141 (JCR Pharmaceuticals): Sales Forecast, till 2030 (USD Million)
Table 19.104 JR-141 (JCR Pharmaceuticals): Risk-Adjusted Market Opportunity, till 2030 (USD Million)

Note: Product cover images may vary from those shown
3 of 4
  • 2-BBB
  • 2X Oncology
  • 4P Therapeutics
  • AB Science
  • Abbott
  • AbbVie
  • Ablynx
  • AC Immune
  • ACADIA Pharmaceuticals
  • Accera
  • Acelot
  • Acorda Therapeutics
  • Actinogen Medical
  • Acumen Pharmaceuticals
  • Adamas Pharmaceuticals
  • Addex Therapeutics
  • Advanced Accelerator Applications
  • Advanced BioHealing
  • Aeolus Pharmaceuticals
  • Aescap Ventures
  • Aestas Pharma
  • Affectis Pharmaceuticals
  • AFFiRiS
  • Agate Medical Investments
  • AgeneBio
  • Agoranov
  • AiCuris
  • Aix-Marseille University
  • Alaska Permanent Fund
  • Alcyone Lifesciences
  • Alector
  • Alkahest
  • Allergan
  • Allinky Biopharma
  • Alnylam Pharmaceuticals
  • Alzinova
  • AlzProtect
  • AMAbiotics
  • Amarantus Therapeutics
  • American Cancer Society
  • American Life Science Pharmaceuticals
  • Amgen
  • Amylyx Pharmaceuticals
  • Anavex Life Sciences
  • Angiochem
  • Antea Group
  • Antoxis
  • Aphios
  • ApoPharma
  • APRINOIA Therapeutics
  • Araclon Biotech
  • Arbor Pharmaceuticals
  • ARCH Venture Partners
  • Archer Pharmaceuticals
  • ArmaGen
  • ARMGO Pharma
  • ArQule
  • Array BioPharma
  • Arrien Pharmaceuticals
  • Arrowhead Pharmaceuticals
  • Artenga
  • Asceneuron
  • ASCIL Biopharm
  • ASEBIO
  • Astellas Pharma
  • AstraZeneca
  • Atlas Venture
  • aTyr Pharma
  • Aurin Biotech
  • Ausio Pharmaceuticals
  • Autifony Therapeutics
  • Avanir Pharmaceuticals
  • Axon Neuroscience
  • Axovant Sciences
  • Axsome Therapeutics
  • AZTherapies
  • Bach Pharma
  • Baillie Gifford
  • Baxter Healthcare
  • Bayer
  • BBB Therapeutics
  • BDC Venture Capital
  • BELLUS Health
  • BenevolentAI Bio
  • Ben-Gurion University
  • BGN Technologies
  • BIAL Group
  • BIND Therapeutics
  • BioAdvance
  • BioAgilytix
  • BioArctic
  • biOasis Technologies
  • Biocat
  • Biocrea
  • BioElectronics
  • Biogen
  • Biohaven
  • BioLineRx
  • BioMarin
  • Bionomics
  • Biotie Therapies
  • Biovista
  • BlueRock Therapeutics
  • Boehringer Ingelheim
  • Boehringer Ingelheim Venture Fund
  • Boston Scientific
  • BpiFrance
  • Brain Biomarker Solutions
  • Brains for Brain Foundation
  • BrainsGate
  • BrainStorm Cell Therapeutics
  • BrainVectis
  • BrainX
  • Brisco Capital Partners
  • Bristol-Myers Squibb
  • Britannia Pharmaceuticals
  • Broad Institute
  • CAAP Creation
  • Caixa Capital Risc
  • Cantabio Pharmaceuticals
  • Capo Therapeutics
  • Carna Biosciences
  • CarThera
  • Cellix Bio
  • Cenna Biosciences
  • CENTOGENE
  • Cerecin (formerly called Accera)
  • Cerecor
  • CereSpir
  • Cerevance
  • CHA Biotech
  • Changchun Huayang High-tech
  • Chaperone Therapeutics
  • Chipscreen
  • Chronos Therapeutics
  • CinnaGen
  • Cipio Partners
  • Clera
  • Clevexel
  • CNRS Innovation
  • Cobra Biologics
  • Cogentis Therapeutics
  • Cognition Therapeutics
  • Cognosci
  • Collaborative Medicinal Development
  • Columbia University
  • Contera Pharma
  • CoPlex Therapeutics
  • Corium International
  • Cornell University
  • Cortexyme
  • Cortice Biosciences
  • Corvitex
  • Crinetics Pharmaceuticals
  • CuraSen Therapeutics
  • Curemark
  • Cyclenium Pharma
  • DAE HWA Pharmaceutical
  • Daewoong Pharmaceutical
  • Dainippon Sumitomo Pharma
  • Dart Pharma
  • Debiopharm
  • Deciphera Pharmaceuticals
  • DEKK-TEC
  • DelMar Pharmaceuticals
  • Denali Therapeutics
  • DermaXon
  • Dexcom
  • Domain Therapeutics
  • Dong-A ST
  • Edunn Biotechnology
  • Eight Roads Ventures
  • EIP Pharma
  • Eisai
  • Elan Pharmaceuticals
  • Eli Lilly
  • Elron Electronic Industries
  • EMD Serono
  • EMulate Therapeutics
  • EnhanX Biopharm
  • Enterin
  • E-Scape Bio
  • Ethris
  • Eureka Eurostars
  • Evercore
  • Evgen Pharma
  • Fabre-Kramer Pharmaceutical
  • Federal Ministry of Education and Research
  • FerroKin BioSciences
  • Fidelity Biosciences
  • FightMND
  • Financière Tuileries
  • Flagship Ventures
  • Flocel
  • Fluorinov Pharma
  • Fondazione Telethon
  • Forest laboratories (a division of Allergan)
  • F-star
  • FUJIFILM Toyama Chemical
  • Fulcrum Therapeutics
  • Fundación MEDINA
  • Gale Capital Solutions
  • GemVax & KAEL
  • Gene Therapy Research Institution
  • Genentech
  • Genervon Biopharmaceuticals
  • Genzyme
  • German Cancer Research Center
  • Gismo Therapeutics
  • GlaxoSmithKline
  • GliaCure
  • GliaPharm
  • GNT Pharma
  • Goldman Sachs
  • Grifols
  • Groupe Arnault
  • Halozyme Therapeutics
  • Haplogen
  • Harvard University
  • Herantis Pharma
  • Heritage Pharmaceuticals
  • HSRx Biopharmaceutical
  • IACTA Pharmaceuticals
  • Innovative California Biosciences International
  • Il Dong Pharmaceutical
  • Immune Pharmaceuticals
  • Immunex
  • Immungenetics
  • Impax Laboratories
  • Impel NeuroPharma
  • ImStar
  • Industrial Technology Research Institute
  • Inflazome
  • Inhibikase Therapeutics
  • Innovate UK
  • Innovative California Biosciences International (ICBI)
  • INSERM-CEA
  • Institute for Research in Immunology and Cancer — Commercialization of Research
  • Intec Pharma
  • Integrative Research Laboratories
  • IntelGenx
  • Intellect Neurosciences
  • International Stem Cell
  • Intra-Cellular Therapies
  • INVENT Pharmaceuticals
  • Io Therapeutics
  • Ionis Pharmaceuticals
  • Iproteos
  • IRB Barcelona
  • Janssen Pharmaceuticals
  • Jazz Pharmaceuticals
  • JCR Pharmaceuticals
  • JEIL Pharmaceuticals
  • Johns Hopkins University
  • Johnson & Johnson
  • Johnson and Johnson Development
  • Jonghoud International
  • Junaxo
  • Kadmon
  • Kainos Medicine
  • KalGene Pharmaceuticals
  • Karuna Pharmaceuticals
  • Khondrion
  • Kinled Holding
  • Kissei Pharmaceutical
  • Korea Drug Development Fund (KDDF)
  • K-PAX Pharmaceuticals
  • Krisani Bio
  • Kyowa Hakko Kirin
  • Lauren Sciences
  • Leland Stanford Junior University
  • Leiden University
  • Lipopharma
  • Living Cell Technologies
  • Lixte Biotechnology
  • Longeveron
  • Longevity Biotech
  • Lonza
  • Lotus Tissue
  • Lumena Pharmaceuticals
  • Lundbeck
  • Luye Pharma Group
  • Lyndra Therapeutics
  • Lysosomal Therapeutics
  • M3 Biotechnology
  • Massachusetts Institute of Technology
  • McGill University
  • Med-Life Discoveries
  • MedDay Pharmaceuticals
  • Medesis Pharma
  • MedGenesis Therapeutix
  • MedImmune
  • MEDIPOST
  • Mediti Pharma
  • Medtronic
  • Melior Pharmaceuticals
  • Merck
  • Metabolic Solutions Development Company
  • Michael J Fox Foundation
  • Michael Smiths Laboratories
  • Minerva Neurosciences
  • Minoryx Therapeutics
  • Mireca Medicines
  • Mission Therapeutics
  • Mitochon Pharmaceuticals
  • Mitsui Global Investment
  • MMV Financial
  • Moderna Therapeutics
  • Momenta Pharmaceuticals
  • Montisera
  • Morgan Stanley
  • Morphotek
  • Movetis
  • Mylan
  • Mylan Laboratories
  • Mystic Pharmaceuticals
  • naNO LIMIT Therapeutics
  • Nanomerics
  • National Cancer Institute
  • National Multiple Sclerosis Society
  • Nektar Therapeutics
  • Neomed Institute of Wellness and Rehabilitation
  • Netherlands Translational Research Center
  • Neuralstem
  • Neuraltus Pharmaceuticals
  • Neuren Pharmaceuticals
  • Neurim Pharmaceuticals
  • NeuroAdjuvants
  • Neurocentria
  • Neurocrine Biosciences
  • NeuroDerm
  • Neurodon
  • Neurogeneration
  • NeuroGenetic Pharmaceuticals
  • Neurolixis
  • Neuron Bio
  • NeuroNascent
  • Neuronix
  • NeurOp
  • Neuropore Therapies
  • NeuroSolis
  • Neurotez
  • NeuroTransit
  • Neurotrope Bioscience
  • NeuroVive Pharmaceutical
  • NEUWAY Pharma
  • New World Laboratories
  • NewGen Therapeutics
  • NexGenix
  • NextSource Biotechnology
  • nLife Therapeutics
  • NLS Pharma
  • Nordic Life Sciences
  • Novartis
  • Novo Nordisk
  • Novogen
  • NPS Pharmaceuticals
  • Nsgene
  • Oligomerix
  • Oncodesign
  • OncoNanoBBB
  • Ono Pharmaceutical
  • OPKO Health
  • OptiNose
  • Orion Pharma
  • Ortho-McNeil Pharmaceutical
  • Oryzon Genomics
  • Osmotica Pharmaceutical
  • Ossianix
  • Otsuka Pharmaceutical
  • Oxalys Pharmaceuticals
  • Oxford BioMedica
  • P2D Bioscience
  • Pain Therapeutics
  • Palobiofarma
  • Panakès Partners
  • Pangu BioPharma
  • Parc Cientific de Barcelona
  • Parke-Davis
  • PeptiDream
  • Peptron
  • Perfusion Technology
  • Pervasis Therapeutics
  • Pfizer
  • Pharma Two B
  • Pharmacia & Upjohn
  • Pharmaphenix
  • Pharmidex
  • Pharnext
  • Pitango Venture Capital
  • Plex Pharmaceuticals
  • Plexxikon
  • Portage Pharmaceuticals
  • Prana Biotechnology
  • Premacure
  • Prexton Therapeutics
  • Priavoid
  • Primary Peptides
  • Proclara Biosciences
  • ProMIS Neurosciences
  • Promius Pharma
  • Protagenic Therapeutics
  • ProteoTech
  • Prothena
  • Protheragen
  • PTC Therapeutics
  • QR Pharma
  • Radio Medix
  • Radius Health
  • Raptor
  • RaQualia Pharma
  • Regenera Pharma
  • RemeGenix
  • reMYND
  • Repligen
  • Retrotope
  • Rett Syndrome Research Trust
  • Reviva Pharmaceuticals
  • Roche
  • Rodin Therapeutics
  • SAGE Therapeutics
  • Sagetis Biotech
  • SalubRx Therapeutics
  • Sandoz
  • Sangamo Therapeutics
  • Saniona
  • Sanofi
  • Santaris Pharma
  • Saol Therapeutics
  • Schering
  • Schering-Plough
  • Schwarz Pharma
  • SciFluor Life Sciences
  • SCR Provençale et Corse
  • Serina Therapeutics
  • Servier
  • Sham Innovation Santé
  • Shanghai Green valley Pharmaceutical
  • Shire
  • Siena Biotech
  • Sihuan Pharmaceutical
  • SiMPore
  • SiNON Therapeutics (formerly known as nano LIMIT Therapeutics)
  • Sinphar Pharmaceutical
  • SK Biopharmaceuticals
  • SmithKline Beecham
  • Solvo Biotechnology
  • Sosei Heptares
  • Southern Research
  • Sovicell
  • Spark Therapeutics
  • Stern Investor Relations
  • Sumitomo Dainippon Pharma
  • Sun Pharma Advanced Research Company
  • Sunovion
  • Supernova Invest
  • Suven Life Sciences
  • Synageva BioPharma
  • Synapse Technologies
  • SynVivo
  • T3D Therapeutics
  • Tactical Therapeutics
  • Takeda Pharmaceuticals
  • Takeda Ventures
  • TauRx Therapeutics
  • TechnoPhage
  • Teikoku Pharma
  • Tetra Therapeutics
  • Teva Pharmaceutical
  • The ALS Association
  • The Campbell Foundation
  • The Hospital for Sick Children (SickKids)
  • Titan Pharmaceuticals
  • Tonix Pharmaceuticals
  • TPG Biotech
  • TransBioTech
  • Transgene
  • Transition Therapeutics
  • TransMolecular
  • Treventis
  • TTY Biopharm
  • UCB
  • United Neuroscience
  • University College London
  • University of Barcelona
  • University of British Columbia
  • University of California
  • University of Connecticut
  • University of Sherbrooke
  • University of Texas
  • University of Washington
  • Uppsala University
  • US WorldMeds
  • Vall d’Hebron Research Institute
  • Vect-Horus
  • VIMAC Milestone Medica Fund
  • Vinnova
  • ViroPharma
  • VistaGen Therapeutics
  • Vivreon Biosciences
  • Vivoryon Therapeutics
  • Voices Against Brain Cancer
  • VoltMed
  • Voyager Therapeutics
  • Wellington Partners
  • WuXi Biologics
  • Xcelthera
  • Xenoport
  • Xinogen
  • Xoc Pharmaceuticals
  • Zambon
  • Zywie
Note: Product cover images may vary from those shown
4 of 4

 

 

Loading
LOADING...

Adroll
adroll